Richard Rosenquist Brandell

Richard Rosenquist Brandell

Professor/Överläkare

Forskar om lymfatiska maligniteter med hjälp av avancerade molekylära tekniker. Leder nationell infrastruktur för precisionsmedicin. Momentansvarig för klinisk genetik inom läkarprogrammet.

Besöksadress: Karolinska Institutet, BioClinicum J10:20, Visionsgatan 4, 17164 Solna
Postadress: K1 Molekylär medicin och kirurgi, K1 MMK Klinisk genetik, 171 76 Stockholm
Del av:

Om mig

  • Sedan 2017 är jag professor i klinisk genetik vid Institutionen för molekylär medicin och kirurgi vid Karolinska Institutet samt överläkare i klinisk genetik vid Karolinska Universitetssjukhuset. Jag erhöll min läkarexamen 1996 och min doktorsexamen 1998 vid Umeå universitet och genomförde därefter en postdoktoral vistelse vid Institutionen för patologi, Frankfurt am Main, Tyskland.

    År 2000 startade jag min forskargrupp vid Institutionen för immunologi, genetik och patologi vid Uppsala universitet med fokus på molekylär karaktärisering av lymfatiska maligniteter. Jag blev docent i medicinsk genetik vid Uppsala universitet 2002, specialist i klinisk genetik vid Akademiska sjukhuset 2004 och utnämndes till professor i molekylär hematologi vid Uppsala universitet 2007.

    Jag initierade och ledde SciLifeLab Clinical Genomics-faciliteten i Uppsala från 2013 till 2017 och var direktör för den nationella Clinical Genomics-plattformen inom SciLifeLab 2016–2021. Sedan 2017 är jag föreståndare för Genomic Medicine Sweden, en nationell infrastruktur för implementering av precisionsdiagnostik/medicin i svensk sjukvård.

Forskningsbeskrivning

  • Genom att använda avancerade molekylära verktyg, inklusive nästa generations sekvenseringstekniker, har jag bidragit till att öka förståelsen för de mekanismer som ligger bakom utvecklingen av lymfatiska maligniteter, särskilt kronisk lymfatisk leukemi (KLL), den vanligaste leukemiformen hos vuxna. Mina studier har identifierat nya prognostiska och prediktiva markörer, definierat kliniskt relevanta undergrupper av KLL och avsevärt förbättrat riskstratificeringen på individnivå.
     
    Mitt team har också presenterat starka bevis för att både autoantigen och mikrobiella antigen spelar en central roll i patogenesen vid KLL. Parallellt har jag byggt upp starka samarbeten nationellt, i Europa och internationellt. Jag är en av fem grundande medlemmar i ett ledande KLL-forskningskonsortium som omfattar mer än 50 000 patienter med KLL från mer än 40 akademiska institutioner.
     
    Genom integrativa multiomikanalyser syftar min forskning till att identifiera molekylära förändringar inom genomet, epigenomet, transkriptomet och proteomet. Genom att koppla dessa förändringar till viktiga signalvägar och regleringsprocesser, ned till singelcellsnivå, strävar mitt team efter att identifiera centrala molekylära drivkrafter bakom sjukdomsprogression och behandlingsresistens. I slutändan kommer detta arbete att fördjupa vår förståelse av uppkomst och utveckling av KLL, möjliggöra upptäckt av nya biomarkörer och identifiera terapimål anpassade till olika patientgrupper, och därigenom driva utvecklingen av precisionsmedicin för denna fortfarande obotliga sjukdom.

Undervisning

  • Jag är momentansvarig för momentet klinisk genetik under termin tio på läkarprogrammet. Jag har varit huvudhandledare för 16 genomförda doktorsavhandlingar, bihandledare för 12 doktorander och handledare för 12 postdoktorala forskare.

Artiklar

Alla övriga publikationer

Forskningsbidrag

  • Vägen till skräddarsydd behandling vid kronisk lymfatisk leukemi
    Cancerfonden
    1 January 2026 - 1 December 2028
  • Svenska KLL-gruppen
    Cancerfonden
    1 January 2026 - 1 December 2028
  • Kartläggning av det komplexa molekylära landskapet vid kronisk lymfatisk leukemi: vägen till precisionmedicin
    Radiumhemmets Forskningsfonder
    1 January 2026 - 1 December 2028
  • Kartläggning av resistensmekanismer mot målinriktade terapier vid kronisk lymfatisk leukemi
    Karolinska Institutet
    1 January 2026 - 1 December 2029
  • Unravelling novel mechanisms of treatment resistance in chronic lymphocytic leukemia using single-cell spatial proteomics
    Cancer Research KI
    1 December 2025 - 1 December 2026
  • Kartläggning av det komplexa molekylära landskapet vid kronisk lymfatisk leukemi: vägen till precisionmedicin
    Vetenskapsrådet
    1 January 2025 - 1 December 2028
  • Kartläggning av det komplexa molekylära landskapet vid kronisk lymfatisk leukemi: vägen till precisionmedicin
    ALF Region Stockholm
    1 January 2025 - 1 December 2027
  • Multimodal explorative testing in the ON-OFF ibrutinib trial in CLL
    Science for Life Laboratory
    1 July 2024 - 1 June 2026
  • Democratising and making sense out of heterogeneous scholarly content (SciLake)
    European Union
    1 January 2023 - 1 March 2026
  • Personalised Cancer Medicine for all EU citizens
    European Union
    1 July 2022 - 1 June 2025
  • The molecular landscape of chronic lymphocytic leukemia
    Swedish Cancer Society
    1 January 2018
    Chronic lymphocytic leukemia (CLL) is the most common form of leukemia in adults and in Sweden there are about 500 people every year diagnosed with CLL. It is a biologically and clinically very heterogeneous disease in which a third of the patients get a relatively kind disease, in one third the symptoms develop more and more, while the last third develops an aggressive disease that does not respond to treatment and where the survival time is short. Currently there is no treatment that cures CLL and there is a great need for new medications, especially for patients with advanced disease. Our strategy is that the best way to develop new medications is to identify and characterize subgroups of patients with different prognoses and different responses to treatment. We have access to a very large collection of samples from CLL patients divided into different subgroups. With the help of advanced sequencing techniques and other molecular analysis methods, we will find out which molecular mechanisms are behind poor or good prognosis or that a treatment works or not. We will also use different techniques to detect new types of drugs or groups of drugs that can improve treatment at CLL. Our goal is to identify biomarkers that can be used to predict the disease development of the individual patient, for example, the time for treatment to be inserted or total survival time. We also hope to find markers that can show whether a treatment causes the disease to go back completely or partially, or if it does not respond at all. In the long term, our results can contribute to the development of new treatments for CLL patients belonging to different subgroups and to methods to determine in advance whether a particular subgroup of patients benefit from a particular treatment, something that is not possible at present.
  • The molecular landscape of chronic lymphocytic leukemia
    Swedish Cancer Society
    1 January 2017
    Chronic lymphocytic leukemia (CLL) is the most common form of leukemia in adults and in Sweden there are about 500 people every year diagnosed with CLL. It is a biologically and clinically very heterogeneous disease in which a third of the patients get a relatively kind disease, in one third the symptoms develop more and more, while the last third develops an aggressive disease that does not respond to treatment and where the survival time is short. Currently there is no treatment that cures CLL and there is a great need for new medications, especially for patients with advanced disease. Our strategy is that the best way to develop new medications is to identify and characterize subgroups of patients with different prognoses and different responses to treatment. We have access to a very large collection of samples from CLL patients divided into different subgroups. With the help of advanced sequencing techniques and other molecular analysis methods, we will find out which molecular mechanisms are behind poor or good prognosis or that a treatment works or not. We will also use different techniques to detect new types of drugs or groups of drugs that can improve treatment at CLL. Our goal is to identify biomarkers that can be used to predict the disease development of the individual patient, for example, the time for treatment to be inserted or total survival time. We also hope to find markers that can show whether a treatment causes the disease to go back completely or partially, or if it does not respond at all. In the long term, our results can contribute to the development of new treatments for CLL patients belonging to different subgroups and to methods to determine in advance whether a particular subgroup of patients benefit from a particular treatment, something that is not possible at present.
  • The molecular landscape of chronic lymphocytic leukemia
    Swedish Cancer Society
    1 January 2016
    Chronic lymphocytic leukemia (CLL) is the most common form of leukemia in adults and in Sweden there are about 500 people every year diagnosed with CLL. It is a biologically and clinically very heterogeneous disease in which a third of the patients get a relatively kind disease, in one third the symptoms develop more and more, while the last third develops an aggressive disease that does not respond to treatment and where the survival time is short. Currently there is no treatment that cures CLL and there is a great need for new medications, especially for patients with advanced disease. Our strategy is that the best way to develop new medications is to identify and characterize subgroups of patients with different prognoses and different responses to treatment. We have access to a very large collection of samples from CLL patients divided into different subgroups. With the help of advanced sequencing techniques and other molecular analysis methods, we will find out which molecular mechanisms are behind poor or good prognosis or that a treatment works or not. We will also use different techniques to detect new types of drugs or groups of drugs that can improve treatment at CLL. Our goal is to identify biomarkers that can be used to predict the disease development of the individual patient, for example, the time for treatment to be inserted or total survival time. We also hope to find markers that can show whether a treatment causes the disease to go back completely or partially, or if it does not respond at all. In the long term, our results can contribute to the development of new treatments for CLL patients belonging to different subgroups and to methods to determine in advance whether a particular subgroup of patients benefit from a particular treatment, something that is not possible at present.
  • Characterization of the molecular landscape in chronic lymphocytic leukemia
    Swedish Cancer Society
    1 January 2015
    Chronic lymphocytic leukemia (CLL) is the most common form of leukemia in adults and in Sweden there are about 500 people every year diagnosed with CLL. It is a biologically and clinically very heterogeneous disease in which a third of the patients get a relatively "kind" disease, in one third the symptoms develop more and more, while the last third develops an aggressive disease that does not respond to treatment and where the survival time is short. Currently there is no treatment that cures CLL and there is a great need for new medications, especially for patients with advanced disease. Our strategy is that the best way to develop new medications is to identify and characterize subgroups of patients with different prognoses and different responses to treatment. We have access to a very large collection of samples from CLL patients divided into different subgroups. With the help of advanced sequencing techniques and other molecular analysis methods, we will find out which molecular mechanisms are behind poor or good prognosis or that a treatment works or not. We will also use different techniques to detect new types of drugs or groups of drugs that can improve treatment at CLL. Our goal is to identify biomarkers that can be used to predict the disease development of the individual patient, for example the time for treatment to be inserted or survival time. We also hope to find markers that can show whether a treatment causes the disease to go back completely or partially, or if it does not respond at all. In the long term, our results can contribute to the development of new treatments for CLL patients belonging to different subgroups and to methods to predetermine whether a particular subgroup of patients benefit from a certain treatment, something that is not possible at present.
  • Characterization of the molecular landscape in chronic lymphocytic leukemia
    Swedish Cancer Society
    1 January 2014
    Chronic lymphocytic leukemia (CLL) is the most common form of leukemia in adults and in Sweden there are about 500 people every year diagnosed with CLL. It is a biologically and clinically very heterogeneous disease in which a third of the patients get a relatively "kind" disease, in one third the symptoms develop more and more, while the last third develops an aggressive disease that does not respond to treatment and where the survival time is short. Currently there is no treatment that cures CLL and there is a great need for new medications, especially for patients with advanced disease. Our strategy is that the best way to develop new medications is to identify and characterize subgroups of patients with different prognoses and different responses to treatment. We have access to a very large collection of samples from CLL patients divided into different subgroups. With the help of advanced sequencing techniques and other molecular analysis methods, we will find out which molecular mechanisms are behind poor or good prognosis or that a treatment works or not. We will also use different techniques to detect new types of drugs or groups of drugs that can improve treatment at CLL. Our goal is to identify biomarkers that can be used to predict the disease development of the individual patient, for example the time for treatment to be inserted or survival time. We also hope to find markers that can show whether a treatment causes the disease to go back completely or partially, or if it does not respond at all. In the long term, our results can contribute to the development of new treatments for CLL patients belonging to different subgroups and to methods to predetermine whether a particular subgroup of patients benefit from a certain treatment, something that is not possible at present.

Anställningar

  • Överläkare i klinisk genetik, ME Klinisk genetik och genomik, Karolinska Universitetssjukhuset, 2017-
  • Professor/Överläkare, Molekylär medicin och kirurgi, Karolinska Institutet, 2017-
  • Professor i molekylär hematologi, Institutionen för immunologi, genetik och patologi, Uppsala universitet, 2007-2017
  • Överläkare i klinisk genetik, Akademiska sjukhuset, 2007-2017
  • Professor/Överläkare, Onkologi-Patologi, Karolinska Institutet, 2010-2012
  • Forskartjänst 50% (finansierad av Cancerfonden), Institutionen för immunologi, genetik och patologi, Uppsala universitet, 2005-2006
  • Överläkare i klinisk genetik, Akademiska sjukhuset, 2004-2006
  • Postdoktoral forskare, Institutionen för immunologi, genetik och patologi, Uppsala universitet, 1999-2005
  • ST i klinisk genetik, Akademiska sjukhuset, 1999-2004
  • Postdoc, Institutionen för medicinsk biovetenskap, Umeå universitet, 1998-1999
  • AT, Norrlands universitetssjukhus, 1997-1999

Examina och utbildning

  • Specialist i klinisk genetik, Akademiska sjukhuset, 2004
  • Docent i medicinsk genetik, Uppsala universitet, 2002
  • Läkarlegitimation, Norrlands universitetssjukhus, 1999
  • Medicine doktor i patologi, Umeå universitet, 1998
  • Läkarexamen, Umeå universitet, 1996

Uppdrag

  • Co-chair, Precision Omics Initiative Sweden (PROMISE), Karolinska Institutet, 2024-
  • Momentansvarig, Moment klinisk genetik, läkarprogrammet, Karolinska Institutet, 2017-
  • Föreståndare, Genomic Medicine Sweden, Karolinska Institutet, 2017-
  • Direktör, SciLifeLab Clinical Genomics platform, Science for Life Laboratory, 2016-2021
  • Facility Director, SciLifeLab Clinical Genomics Uppsala, Uppsala universitet, 2013-2017
  • Medicinskt ledningsansvarig, Cancergenetik, Akademiska sjukhuset, 2005-2012

Priser och utmärkelser

  • Årets läkemedelsprofil, 2025
  • Årets cancernätverkare - utsedd av Nätverket mot cancer, 2022
  • Wallenberg Clinical Scholar, 2017
  • Landstinget i Uppsala läns forskningspris, 2013
  • European Hematology Association Fellowship, 2006
  • Uppsalas Fernströmpris, 2005

Handledning

  • Handledning till doktorsexamen

    • Fatemah Rezayee, 2025
    • Cecilia Arthur, 2023
    • Svea Stratman, 2021
    • Mattias Mattsson, 2020
    • Emma Young, 2017
    • Sujata Bhoi, 2017
    • Fredrik Baecklund, 2017
    • Panagiotis Baliakas, 2016
    • Diego Cortese, 2016
    • Ann-Charlotte Bergh, 2016
    • Viktor Ljungström, 2016
    • Markus Mayrhofer, 2015
    • Nicola Cahill, 2012
    • Lesley Ann Sutton, 2012
    • Anna Margret Halldorsdottir, 2011
    • Millaray Marincevic, 2010
    • Marie Sevov, 2010
    • Rebeqa Gunnarsson, 2010
    • Norafiza Zainuddin, 2010
    • Afsaneh Roshanai, 2010
    • Arifin Kaderi, 2010
    • Maria Norberg, 2010
    • Ingrid Thörn, 2009
    • Fiona Murray, 2008
    • Emma Flordal Thelander, 2007
    • Sarah Walsh, 2004
    • Gerard Tobin, 2004
    • Mia Thorsélius, 2004

Uppdrag i kommitté

  • Ordförande, Prioriteringskommitté (BIOIII), Barncancerfonden, 2023-
  • Medlem, Styrgrupp för Nollvision cancer, 2023-2024
  • Medlem, Styrgrupp för Testbed Sweden Precision Health Cancer, 2022-
  • Medlem, Kommittén för forskning, Karolinska Institutet, 2020-2026
  • Medlem, Styrgrupp för infrastrukturen PREDICT, Umeå universitet, 2020-
  • Medlem, Nobelförsamlingen, Karolinska Institutet, 2019-
  • Medlem, Utbildningsnämnden, Institutionen för molekylär medicin och kirurgi, Karolinska Institutet, 2017-
  • Medlem, Forskarutbildningsnämnden, Institutionen för molekylär medicin och kirurgi, Karolinska Institutet, 2017-2021
  • Ordförande, FoUU-gruppen ME Klinisk genetik och genomik, Karolinska Institutet, 2017-
  • Medlem, Styrgrupp för Centrum för Translationell Genomik (CTG), Lunds universitet, 2017-
  • Medlem, Prioriteringskommitté (BIOIII), Barncancerfonden, 2015-
  • Medlem, Nordiska KLL-gruppen, 2015-
  • Medlem, Prioriteringskommitté för Young Investigator Award, Cancerfonden, 2008-2014
  • Medlem, Institutionsledning, Institutionen för immunologi, genetik och patologi, Uppsala universitet, 2008-2010
  • Medlem, Prioriteringskommitté (PkD), Cancerfonden, 2007-2012
  • Medlem, Styrgrupp för Svenska KLL-gruppen, 2004-
  • Annat, Sekreterare, Svenska KLL-gruppen, 2004-2010

Gästforskning och resestipendier

  • Postdoc, University of Frankfurt, 2002-2003

Nyheter från KI

Kalenderhändelser från KI

Nyheter från externa medier